Jump to content

Paracentesis and Thoracentesis

From WikiMesothelioma — Mesothelioma Knowledge Base


Paracentesis & Thoracentesis for Mesothelioma

Paracentesis & Thoracentesis
Procedure Type Needle-based fluid drainage (diagnostic and therapeutic)
Thoracentesis Target Pleural space (chest cavity)
Paracentesis Target Peritoneal cavity (abdomen)
Effusion Prevalence (Pleural) 54–90% of MPM patients at diagnosis
Cytology Sensitivity 45.1% for mesothelioma (vs 64.3% for any malignancy)
BAP1 + MTAP Combined 78.9% sensitivity, 100% specificity
Ultrasound Benefit Reduces pneumothorax 19%, bleeding 68%
Recurrence Rate 98% within 30 days (MPE)
Trapped Lung Rate ~33% of mesothelioma MPE cases
Primary Guidelines BTS 2023, NCCN 2025, ATS/STS/STR 2018
CPT Code (Thoracentesis) 32554 (without imaging), 32555 (with imaging)
Key Facts: Paracentesis & Thoracentesis for Mesothelioma
  • Thoracentesis (pleural tap) drains fluid from the chest cavity, while paracentesis (abdominal tap) drains fluid from the peritoneal cavity — both serve diagnostic and therapeutic purposes in mesothelioma[1][2]
  • Pleural effusion occurs in approximately 90% of malignant pleural mesothelioma patients, making thoracentesis one of the most commonly performed procedures in this cancer[3][4]
  • Thoracentesis cytology has a pooled sensitivity of only 45.1% for mesothelioma diagnosis — significantly lower than lung cancer (73.8%) or breast cancer (82.0%)[5]
  • The combination of BAP1 and MTAP immunohistochemistry on cell block specimens achieves 78.9% sensitivity and 100% specificity for distinguishing mesothelioma from reactive mesothelial proliferations[6]
  • Ultrasound-guided thoracentesis is now the standard of care, reducing pneumothorax risk by 19% and bleeding complications by 68% compared to unguided procedures[7][8]
  • Malignant pleural effusions recur in 98% of cases within 30 days of a single thoracentesis, with a mean reaccumulation time of just 4.2 days[9][3]
  • Non-expandable (trapped) lung complicates approximately one-third of mesothelioma MPE cases and is an independent predictor of shorter survival (HR 1.80)[10]
  • Indwelling pleural catheters (IPCs) are now recommended as first-choice management for malignant pleural effusions by the 2023 BTS guidelines[11]
  • Tumor tract seeding after chest wall procedures has been reported in up to 51% of mesothelioma patients, though prophylactic irradiation of tracts (PIT) is no longer recommended routinely[12][13]
  • Large-volume thoracentesis (>1.5 liters) carries only a 0.75% risk of re-expansion pulmonary edema, challenging the traditional arbitrary volume limit[14]
  • Thoracentesis with imaging guidance costs $319–$451 (physician fee) compared to $618–$630 (hospital outpatient APC payment), while iatrogenic pneumothorax adds an estimated $18,000 in excess costs[15][16]

What Are Thoracentesis and Paracentesis?

Thoracentesis — also called pleural tap, pleural aspiration, or thoracocentesis in British medical terminology — is a needle-based procedure designed to remove fluid that has accumulated in the pleural space surrounding the lungs.[3][1] The procedure serves two fundamental purposes in mesothelioma care: diagnostic evaluation of the fluid through cytology, biochemistry, and microbiology testing, and therapeutic relief of symptoms caused by large-volume fluid buildup including dyspnea (shortness of breath), persistent cough, chest heaviness, and reduced exercise tolerance.[2][4]

Paracentesis — known alternatively as abdominal tap, peritoneal tap, or ascitic tap — is the corresponding procedure for draining fluid from the peritoneal cavity within the abdomen.[17][12] In patients with peritoneal mesothelioma, paracentesis addresses malignant ascites, which causes abdominal distension, early satiety, nausea, difficulty breathing from diaphragmatic splinting, and significantly reduced mobility.[17][18]

Both procedures are performed using a thin needle or catheter inserted through the skin under local anesthesia, typically guided by ultrasound imaging to identify safe insertion sites and avoid vital structures.[16][19] While both provide important diagnostic information and meaningful symptomatic relief, the temporary nature of that relief — particularly in mesothelioma where fluid reaccumulates rapidly — means these procedures often serve as the starting point in a continuum of increasingly definitive fluid management strategies.[9][20]

How Common Are Malignant Effusions in Mesothelioma?

Pleural effusion is one of the earliest and most prevalent clinical manifestations of malignant pleural mesothelioma (MPM), making thoracentesis an integral part of the diagnostic and treatment pathway for the vast majority of patients.[3][4] A prospective single-center cohort study of 229 patients found that 82.7% had pleural effusion at initial presentation, while other sources report the prevalence ranging from 54% to 94% across all MPM cases.[10][3][1]

The pathophysiology of malignant pleural effusion in mesothelioma involves multiple mechanisms working in concert. Tumor cells obstruct lymphatic drainage pathways that normally clear fluid from the pleural space. Tumor-immune cell interactions increase capillary permeability, allowing additional fluid to leak into the pleural cavity. Mesothelioma cells themselves may directly secrete fluid, and the resulting effusion is biologically active — paradoxically protecting tumor cells from chemotherapy while promoting further tumor growth.[21][22][3] Effusion volumes can exceed two liters, causing significant respiratory compromise and substantially reduced quality of life.[9][23]

For peritoneal mesothelioma, malignant ascites represents the hallmark presenting feature, with progressive fluid accumulation in the abdominal cavity leading to the symptoms that ultimately prompt medical evaluation and diagnosis in many patients.[18][17] Unlike pleural mesothelioma where imaging often reveals the tumor before fluid analysis, peritoneal mesothelioma is frequently discovered during the diagnostic workup of unexplained ascites that proves resistant to conventional treatment.[24][25]

What Happens During a Thoracentesis Procedure?

Pre-Procedure Preparation and Ultrasound Guidance

The 2023 British Thoracic Society (BTS) Pleural Disease Guidelines strongly recommend that image-guided thoracentesis should always be used to reduce the risk of complications, establishing this as the modern standard of care.[19][16] This recommendation represents a significant evolution from earlier practice when many thoracenteses were performed without imaging guidance, resulting in considerably higher complication rates.[26][15]

The evidence supporting ultrasound guidance is compelling. A meta-analysis of over 61,000 thoracenteses demonstrated that ultrasound guidance reduces the risk of pneumothorax by 19% (OR 0.81; 95% CI, 0.74–0.90) and reduces bleeding complications by 68%.[7] In a focused study of 445 patients with malignant pleural effusion, ultrasound-guided thoracentesis achieved a pneumothorax rate of just 1% versus 9% without ultrasound guidance (P < 0.0001).[8][27] Beyond safety improvements, ultrasound guidance has been shown to decrease hospital costs by $2,075, reduce length of stay by 1.5 days, and lower in-hospital mortality from 7.4% to 4.2%.[16]

Patient Positioning and Needle Insertion

Standard positioning places the patient sitting upright, leaning forward over a bedside table to allow gravity to pool the effusion at the lowest point of the pleural space.[16][28] The insertion site is typically along the posterior axillary line or midscapular line, one to two intercostal spaces below the fluid level as identified by ultrasound.[16]

The needle is carefully inserted above the rib margin to avoid the neurovascular bundle — containing the intercostal artery, vein, and nerve — that runs along each rib's inferior surface.[16][29] This anatomical consideration is particularly important near the spine, where the intercostal artery is less protected by the overlying rib. Research has shown that only 17% of intercostal arteries were shielded by the rib at 3 cm lateral to the spine, compared to 97% at 6 cm lateral, underscoring the importance of proper site selection.[16]

Volume Limits and Re-Expansion Pulmonary Edema

Traditional guidelines recommended limiting fluid drainage to 1.0–1.5 liters per session to prevent re-expansion pulmonary edema (RPE), a potentially serious complication where rapid lung re-expansion causes fluid to leak into the alveoli.[16][30] However, landmark research has challenged this arbitrary volume limit, demonstrating that clinical and radiographic RPE after large-volume thoracentesis is rare and independent of the volume removed, pleural pressures, or pleural elastance.[14]

Among patients who had more than 1.5 liters removed, the RPE rate was only 0.75% (6 of 799 patients), and no patient died from RPE.[14] Current best practice recommends stopping drainage if the patient develops chest discomfort, if resistance to aspiration is felt suggesting lung contact with the needle, or if pleural pressure drops below −20 cm H₂O on manometry.[31][16] Routine post-procedure chest X-ray is increasingly considered unnecessary when the patient remains asymptomatic, with the 2023 BTS guidelines supporting imaging only when symptoms suggest a complication.[19]

What Happens During a Paracentesis Procedure?

Paracentesis for peritoneal mesothelioma follows principles similar to thoracentesis but adapted for the abdominal anatomy.[17][25] The patient is positioned supine with slight left lateral decubitus tilt to pool ascitic fluid toward the insertion site. The left lower quadrant is the most commonly used insertion point, chosen to avoid surgical scars, the inferior epigastric vessels, and abdominal organs.[17][32] Ultrasound guidance helps identify safe insertion sites and ensures avoidance of bowel loops that may be adherent to the abdominal wall.[17]

A Z-track technique is routinely employed, where the needle enters the skin at an angle and then the tract is redirected before entering the peritoneal cavity. This creates an oblique path that seals when the needle is removed, preventing persistent fluid leakage — a particularly common complication when ascites is tense and intra-abdominal pressure is elevated.[17][32]

In malignant ascites from peritoneal mesothelioma, large-volume paracentesis (LVP) can often be performed more liberally than in cirrhotic ascites. This is because the pathophysiology of malignant ascites differs fundamentally from portal hypertension-driven ascites. Paracentesis-induced circulatory dysfunction (PICD) — the hemodynamic instability that can occur when large fluid volumes are removed — is primarily a concern in cirrhotic patients rather than those with malignant ascites.[32][17] Nevertheless, intravenous fluids may be administered to prevent hypotension during large-volume drainage.[17]

The limitations of paracentesis mirror those of thoracentesis: relief is effective but temporary. Fluid reaccumulates progressively, and repeated drainage leads to significant protein loss (ascitic fluid protein content is substantial), contributing to hypoalbuminemia and malnutrition that can compound the cachexia already common in advanced peritoneal mesothelioma.[25][33] Over time, fluid may accumulate in loculated pockets as adhesions form, making drainage progressively more difficult with each subsequent procedure.[34]

How Effective Is Fluid Analysis for Diagnosing Mesothelioma?

Pleural Fluid Cytology Sensitivity

The diagnostic sensitivity of thoracentesis cytology for mesothelioma is notably lower than for other malignancies, representing one of the most significant limitations of this procedure as a diagnostic tool.[5][35] A landmark 2022 meta-analysis from MD Anderson Cancer Center, encompassing 8 studies and 1,133 patients, reported a pooled cytologic sensitivity of only 45.1% (95% CI, 24.9–66.1%) for mesothelioma.[5]

Cancer Type Pooled Cytology Sensitivity Studies Patients
Any malignancy 64.3% (95% CI 59.2–69.2%) 29 5,444
Mesothelioma 45.1% (95% CI 24.9–66.1%) 8 1,133
Lung cancer 73.8% (95% CI 65.9–83.6%) 12 1,184
Breast cancer 82.0% (95% CI 70.0–91.7%) 9 532

Data from Martinez-Zayas et al., 2022 meta-analysis[5]

The low sensitivity reflects the fundamental challenge of distinguishing malignant mesothelial cells from reactive mesothelial cells under the microscope — a distinction that can confound even experienced cytopathologists.[36][27] Additionally, sarcomatoid mesothelioma, which accounts for approximately 10–20% of cases and carries the worst prognosis, rarely sheds identifiable cells into the effusion fluid.[5][35] Cell block preparation combined with immunohistochemistry significantly improves diagnostic yield over standard cytology smear alone.[36]

By contrast, thoracoscopy with pleural biopsy achieves a pooled sensitivity of 91.5% (95% CI, 87.1–95.2%) across 15 studies and 453 patients — roughly double the diagnostic yield of cytology alone.[5][37]

Peritoneal Fluid Cytology

Paracentesis cytology for peritoneal mesothelioma shows similarly limited sensitivity. One study detected mesothelioma cells in only 34% of 46 peritoneal ascites samples, while the overall sensitivity of ascitic fluid cytology for malignancy-related ascites ranges from 58% to 75%.[38][18] Serial sampling and definitive tissue biopsy — whether through omental biopsy or diagnostic laparoscopy — are frequently required to establish a conclusive peritoneal mesothelioma diagnosis.[39][24]

Fluid Biochemistry

Mesothelioma effusions are always exudative, meeting Light's criteria: pleural fluid protein-to-serum protein ratio greater than 0.5, pleural fluid LDH-to-serum LDH ratio greater than 0.6, or pleural fluid LDH exceeding two-thirds the upper limit of normal serum LDH.[40][3] Low pleural fluid pH (below 7.2) carries prognostic significance and predicts poorer pleurodesis success, making pH measurement a useful component of the initial fluid analysis.[40][41]

Hyaluronic acid (HA) was historically investigated as a mesothelioma-specific pleural fluid marker. Early research found elevated HA in 13 of 14 confirmed mesothelioma patients with zero false positives among 56 controls, though using a diagnostic cutoff of >100 µg/mL, sensitivity dropped to only 36.8%.[42][43] The combination of low CEA with high HA can help differentiate mesothelioma from lung carcinoma, yielding a post-test probability for mesothelioma of 81%.[43]

For peritoneal mesothelioma ascites, the serum-ascites albumin gradient (SAAG) typically shows a low-SAAG pattern (less than 1.1 g/dL) consistent with malignant ascites, though sensitivity is approximately 80% and atypical patterns have been reported, adding to diagnostic complexity.[44][39]

What Role Do BAP1 and MTAP Markers Play in Diagnosis?

The application of BAP1 and MTAP immunohistochemistry (IHC) to effusion cell block specimens represents one of the most significant recent advances in mesothelioma diagnosis through fluid analysis, substantially narrowing the gap between cytologic and surgical biopsy diagnostic accuracy.[45][6]

BAP1 (BRCA1-Associated Protein 1) loss detected by IHC on effusion cell blocks has emerged as a powerful adjunct marker. In a study of 279 patients that included 59 biopsy-confirmed mesotheliomas, 100 benign effusions, and 47 adenocarcinomas, BAP1 loss was identified in 57% (43 of 75) of mesotheliomas with zero false positives among adenocarcinomas (0 of 47).[46][47] A meta-analysis confirmed this performance, reporting specificity of 95.7% and sensitivity of 54.7% for BAP1 loss in effusion cytology.[48]

Marker Sensitivity Specificity Evidence Base
BAP1 alone 54–62.2% ~96% Multiple studies[46][49]
MTAP alone Variable High Emerging data[49]
BAP1 + MTAP combined 77.8–78.9% 100% Cell block studies[49][6]

The combined power of these markers is remarkable. A 2022 study of 162 mesothelioma patients (71 cytologic, 91 histologic) demonstrated that loss of BAP1 and/or MTAP differentiated mesothelioma from reactive mesothelial proliferations with 100% specificity and 78.9% sensitivity in effusion cytology — performance comparable to the 80.2% sensitivity achieved in histopathologic tissue sections.[6][41] Importantly, there was 100% concordance between cytologic and corresponding histopathologic samples, meaning that when BAP1/MTAP loss is detected on a cell block, the same finding will be present on subsequent surgical biopsy.[6]

A critical interpretive caveat exists: BAP1 loss in mesothelial cells should generate a high index of suspicion for mesothelioma, but positive BAP1 staining (retention) does not exclude the diagnosis. Only approximately 50–60% of mesotheliomas demonstrate BAP1 loss, meaning roughly 40–50% retain normal BAP1 expression.[46][47] Additionally, a valid internal positive control — BAP1 staining in non-neoplastic inflammatory cells on the same specimen — is an absolute prerequisite before interpreting BAP1 negativity in mesothelial cells.[46]

What Are the Risks and Complications?

Thoracentesis Complications

Thoracentesis is generally a safe procedure, particularly when performed with ultrasound guidance, but carries a defined complication profile that patients and clinicians should understand.[16][29]

Complication Incidence Notes
Overall complication rate 4.1% (95% CI 2.5–6.1%) 23 studies, 32,863 procedures[5]
Pneumothorax (US-guided) 2.5% (95% CI 1.7–3.4%) 36 studies, 66,359 procedures[5]
Pneumothorax (expert operator) 0.6% 9,320 procedures[16]
Pneumothorax (without US) 4–30% Historical rates[26]
Pneumothorax (US, cancer patients) 0.83–1.2% Real-time US guidance[50][51]
Bleeding/hemothorax 0.01–0.18% Very rare with US guidance[16]
Re-expansion pulmonary edema 0.01–0.5% Symptomatic RPE rare[16][14]
RPE with >1.5L removed 0.75% (6/799) No deaths from RPE[14]

Pneumothorax remains the most common complication but has decreased dramatically with the widespread adoption of ultrasound guidance. A 2010 systematic review reported an overall historical pneumothorax rate of 6.0%, with 34.1% of those pneumothoraces requiring chest tube insertion (translating to 1.7% of all thoracenteses needing a chest tube).[52][15] Iatrogenic pneumothorax adds an estimated 4.4 days to hospital stay and approximately $18,000 in additional healthcare costs.[16]

Re-expansion pulmonary edema (RPE) is uncommon and generally self-limiting. Although RPE rates as high as 16% appear in some literature, these figures are inflated by inclusion of asymptomatic radiographic findings that require no treatment. Clinically significant, symptomatic RPE occurs in approximately 0.01–0.5% of procedures and is manageable with supplemental oxygen or BiPAP ventilatory support.[14][16][53]

Paracentesis Complications

Paracentesis carries a generally favorable safety profile with a lower overall complication rate than thoracentesis.[34][32] Persistent leak from the puncture site is the most common issue, particularly with tense ascites, and is managed with wound care or suture placement. Bleeding is rare but risk increases in patients with coagulopathy. Bowel perforation is very rare when ultrasound guidance is employed. Hypotension can occur during large-volume drainage, mitigated by intravenous fluid administration. Infection or peritonitis is uncommon with proper sterile technique.[17][34]

How Does Tumor Tract Seeding Affect Mesothelioma Patients?

Mesothelioma has a well-recognized and distinctive propensity for seeding along procedure tracts — a phenomenon where tumor cells implant along the path created by needles, chest tubes, or thoracoscopy ports, growing as subcutaneous nodules that can become painful and disfiguring.[12][54] Subcutaneous metastases at intervention sites have been reported in up to 51% of patients in some series, making this a significant concern specific to mesothelioma that is not commonly seen with other malignancies.[55][56]

The major PIT (Prophylactic Irradiation of Tracts) trial addressed this issue directly, randomizing 374 patients to receive prophylactic radiotherapy (21 Gy in 3 fractions) or no PIT after chest wall intervention. The trial concluded that PIT is not justified in routine treatment of malignant pleural mesothelioma.[13][57] The SMART trial (over 200 patients) similarly found no meaningful benefit, with a number needed to treat of 25.1 to prevent a single painful procedure tract metastasis (PTM).[58][53]

However, a meta-analysis of 5 randomized controlled trials encompassing 737 patients showed a statistically significant but modest reduction in PTM odds with PIT (OR 0.55; 95% CI, 0.32–0.95), suggesting some patients might benefit despite the overall negative trial results.[55][59] Current ERS/ESTS/EACTS/ESTRO and ESMO guidelines confirm that prophylactic irradiation of tracts is not justified in routine practice, though local palliative radiotherapy remains indicated for the treatment of painful nodules when they develop.[13][56]

When Should Patients Transition to Definitive Procedures?

Given the 98% recurrence rate of malignant pleural effusion within 30 days of thoracentesis, mesothelioma patients frequently face a transition from initial diagnostic/therapeutic drainage to more definitive fluid management strategies.[9][23] Patients often require drainage every 1–4 weeks, creating a substantial burden in terms of hospital visits, symptom recurrence cycles, and cumulative protein/albumin depletion — pleural fluid protein content typically ranges from 30–40 g/L, meaning each liter drained removes a clinically significant amount of protein.[22][3]

Decision Framework

The 2023 BTS guidelines recommend indwelling pleural catheters as first-choice management for malignant pleural effusion.[11] The decision between continued serial thoracentesis, IPC placement, and pleurodesis depends on several patient-specific factors:[11][28]

Lung expandability is the most critical determinant. If the lung fully re-expands after fluid removal, pleurodesis — creating adhesion between the lung surface and chest wall to prevent fluid reaccumulation — is a viable option. If trapped lung is present (approximately 33% of mesothelioma MPE cases), pleurodesis will not work because the lung cannot appose the chest wall, and management relies on IPC or continued thoracentesis.[10][11]

Expected survival influences cost-effectiveness. IPC appears most cost-effective when survival is less than 14 weeks. For patients with very limited prognosis, repeat aspiration may be the most appropriate approach.[60][20]

Patient preference plays an increasingly recognized role. IPCs allow home-based drainage on the patient's own schedule, reducing hospital visits and providing greater autonomy.[61][62]

IPC vs Pleurodesis Comparison

Feature Indwelling Pleural Catheter (IPC) Talc Pleurodesis
Dyspnea relief >75% improvement >75% improvement
Hospital stay Shorter (12.4 days vs 16 days) Longer
Adverse events Higher (OR 4.7) Lower
Spontaneous pleurodesis rate Up to 50% within 3 months 60–80% success rate
Pleural infection risk 9.6% 1.9%
Best suited for Limited survival, trapped lung Expandable lung, longer prognosis

Data from TIME2 trial (JAMA 2012), population-based cohort studies, and IPC efficacy analyses[61][63][64]

IPCs provide symptom relief in 85% of patients regardless of whether the effusion is from mesothelioma or another malignancy.[64][62] A notable advantage of IPCs is that spontaneous pleurodesis occurs in up to half of IPC patients within three months — meaning the catheter can sometimes be removed after the pleural space obliterates naturally.[64][61]

How Does Ultrasound Guidance Improve Safety?

Ultrasound use for thoracentesis is now universally supported by all major guidelines and represents one of the most impactful patient safety improvements in pleural medicine over the past two decades.[19][16][15]

The evidence base is extensive. Beyond the pneumothorax and bleeding reductions described earlier, a large cohort study of over 61,000 thoracenteses confirmed a 19% reduced risk of pneumothorax with ultrasound guidance.[7][27] Pre-procedure ultrasound marking of the insertion site represents the minimum standard, while real-time guidance — continuous visualization during needle insertion — offers additional benefits for small, loculated, or septated effusions and challenging patient anatomy.[16][29]

Thoracic ultrasound also provides valuable diagnostic information beyond simply identifying fluid collections. Sonographic features including pleural thickening patterns, nodular pleural studding, and complex septated effusions can raise suspicion for mesothelioma even before any fluid is withdrawn or biopsied.[11][19] The 2023 BTS guidelines specifically note that thoracic ultrasound may serve as a useful diagnostic tool to support clinical suspicion of pleural malignancy when appropriate sonographic skills are available.[19]

What Are the Costs of These Procedures?

Understanding the cost structure of thoracentesis and paracentesis helps patients and families navigate the financial aspects of mesothelioma care and underscores the economic rationale for ultrasound guidance and appropriate escalation to definitive procedures.[15][20]

CPT Code Description Physician Fee (Non-Facility) Physician Fee (Facility) APC Payment
32554 Thoracentesis without imaging $222–$402 $84–$93 $618–$630
32555 Thoracentesis with imaging $319–$451 $116 $618–$630
49082 Paracentesis without imaging $210 $77 $786

Data from 2026 Medicare Fee Schedule and Argon Medical reimbursement guide[65][66]

A cost-effectiveness analysis found that IPCs are cost-effective compared to talc pleurodesis at $10,870 per quality-adjusted life year (QALY) gained, with IPC being less costly with a probability exceeding 95% of being cost-effective when patient survival is less than 14 weeks.[60][15] However, if significant nursing time (more than 2 hours per week) is required for catheter drainage assistance, the cost-effectiveness advantage narrows substantially.[60]

A population-based cohort study found that IPC patients had lower 12-month mean healthcare costs (CA$40,179 vs CA$46,640) and shorter hospital stays (12.4 days vs 16 days) compared to pleurodesis patients.[63][30] These cost considerations are particularly relevant for mesothelioma patients who may undergo dozens of drainage procedures over the course of their illness.[20]

What Do Current Guidelines Recommend?

BTS 2023 Pleural Disease Guidelines

The 2023 British Thoracic Society guideline represents the most comprehensive and up-to-date evidence-based guidance for managing pleural effusions in mesothelioma:[11][19]

  • Image-guided thoracentesis should always be used — strong recommendation by consensus[19]
  • Blind (non-image-guided) pleural biopsies should not be conducted — strong recommendation by consensus[19]
  • For suspected mesothelioma: imaging-guided pleural biopsy is recommended simultaneously with fluid aspiration or thoracoscopy, rather than waiting for cytology results[11]
  • IPC recommended as first-choice management for MPE[11]
  • For patients with expandable lungs: IPC or talc pleurodesis are both acceptable[11]
  • For trapped lung: IPC is the recommended approach[11]
  • For limited prognosis: repeat aspiration is suggested as the most appropriate strategy[11]

Other Key Guidelines

The ATS/STS/STR 2018 guidelines and ASCO 2018 provisional clinical opinion support ultrasound-guided thoracentesis as the initial intervention for symptomatic malignant pleural effusion, with escalation to IPC or pleurodesis based on patient-specific factors including lung expandability, expected survival, and patient preference.[67][23] The NCCN Mesothelioma guidelines (version 2025) similarly endorse this stepwise approach.[28][22]

All major guidelines now confirm that prophylactic irradiation of tracts (PIT) is not justified in routine practice for mesothelioma patients undergoing pleural procedures, based on the definitive PIT and SMART trial results.[13][56]

What Emerging Technologies Are Being Developed?

Molecular Biomarkers in Pleural Fluid

Beyond standard cytology, pleural fluid is increasingly analyzed for molecular biomarkers that may improve diagnostic accuracy without requiring surgical biopsy. Soluble mesothelin-related peptide (SMRP/mesothelin), fibulin-3, and osteopontin are all under investigation as adjunctive markers for mesothelioma detection in effusion fluid.[49][36][35] BAP1 and MTAP IHC on cell block specimens represent the most significant clinical advance to date, with their combined sensitivity of approximately 79% and 100% specificity potentially reducing the need for surgical biopsy in select cases where the diagnosis can be confirmed on cytology alone.[6][41]

Genomic and Liquid Biopsy Approaches

Next-generation sequencing (NGS) can now be performed on mesothelioma effusion specimens, enabling comprehensive genomic profiling without tissue biopsy. Cell-free DNA analysis and circulating tumor cell detection from pleural fluid represent active research frontiers that may eventually enable non-invasive molecular characterization of mesothelioma, identifying actionable mutations and informing treatment selection.[68][36][37]

AI-Assisted Cytology

Artificial intelligence and deep learning models are being explored for automated mesothelioma cell identification in effusion specimens.[68] These technologies have the potential to address the historically low cytologic sensitivity by identifying subtle morphologic patterns that may escape human detection, though clinical validation is still in early stages.[68][39]

Frequently Asked Questions

Is thoracentesis painful?

Thoracentesis is performed under local anesthesia, and most patients report only pressure or mild discomfort during the procedure rather than sharp pain. The initial injection of lidocaine at the needle insertion site causes a brief stinging sensation. During fluid withdrawal, some patients experience a pulling or tugging sensation, and as the lung re-expands patients may feel chest tightness or an urge to cough. The entire procedure typically takes 15–30 minutes. Severe pain during the procedure may indicate the needle is contacting the lung surface and signals the operator to stop drainage.[1][2][16]

How often will I need thoracentesis repeated?

For mesothelioma patients, fluid reaccumulates rapidly — 98% of malignant pleural effusions recur within 30 days, with a mean reaccumulation time of 4.2 days. Many patients initially require drainage every 1–4 weeks. If you are needing frequent repeat drainage, your medical team will likely discuss transitioning to an indwelling pleural catheter (IPC) or pleurodesis to provide more durable symptom control.[9][3][23]

Can thoracentesis definitively diagnose mesothelioma?

Thoracentesis cytology alone diagnoses mesothelioma in only about 45% of cases. However, when BAP1 and MTAP immunohistochemistry are performed on cell block specimens from the fluid, sensitivity improves to approximately 79% with 100% specificity. A negative cytology result does not rule out mesothelioma — most patients will require thoracoscopic biopsy, which achieves over 91% diagnostic sensitivity, for definitive confirmation.[5][6][27]

What is trapped lung, and how does it affect my treatment options?

Trapped lung (non-expandable lung) occurs when the lung cannot fully re-expand after fluid drainage because mesothelioma tumor or fibrous tissue encases the lung surface. This affects approximately one-third of mesothelioma patients with pleural effusion. Trapped lung is important because pleurodesis — the procedure that seals the pleural space to prevent fluid reaccumulation — cannot work if the lung doesn't fully expand. Patients with trapped lung are typically managed with an indwelling pleural catheter instead.[10][11][28]

Is paracentesis different from thoracentesis?

The fundamental principle is the same — using a needle to drain accumulated fluid — but the anatomical targets differ. Thoracentesis drains fluid from the pleural space around the lungs (relevant to pleural mesothelioma), while paracentesis drains fluid from the peritoneal cavity in the abdomen (relevant to peritoneal mesothelioma). Paracentesis generally allows larger volume drainage with less concern for hemodynamic complications compared to cirrhotic ascites, since malignant ascites has different pathophysiology.[17][32][25]

Should I request ultrasound guidance for my procedure?

Yes. All major guidelines including the 2023 BTS guidelines strongly recommend ultrasound-guided thoracentesis as the standard of care. Ultrasound reduces pneumothorax risk by 19%, reduces bleeding by 68%, decreases hospital costs, and improves outcomes. If your facility does not routinely use ultrasound guidance, it is reasonable to request it or seek care at a facility that provides it.[19][7][15]

What happens to the fluid that is drained?

The drained fluid is sent to the laboratory for multiple analyses. Biochemical tests (protein, LDH, pH, glucose) help classify the effusion. Cytology examines the fluid for malignant cells. Immunohistochemistry — particularly BAP1 and MTAP staining on cell blocks — can help identify mesothelioma. Microbiology testing rules out infection. In some cases, molecular testing including next-generation sequencing can be performed on the fluid specimen to guide treatment decisions.[3][36][29]

Are there financial assistance options for these procedures?

Yes. Most health insurance plans cover thoracentesis and paracentesis as medically necessary procedures. Medicare covers these procedures under standard physician fee schedules. For mesothelioma patients specifically, treatment costs including diagnostic and palliative procedures may be recoverable through asbestos trust fund claims, mesothelioma lawsuits, or VA benefits for eligible veterans. Consultation with a mesothelioma attorney can help identify all potential compensation sources.[15][20][4]

Free, Confidential Case Evaluation

Call (866) 222-9990 or visit dandell.com/contact-us

No upfront fees • Experienced representation • National practice


⚠ Statute of Limitations Warning: Filing deadlines vary by state from 1-6 years from diagnosis. Texas allows 2 years from diagnosis or discovery. Contact an attorney immediately to preserve your rights.

References

  1. ↑ 1.0 1.1 1.2 1.3 Mesothelioma Treatment Options, Danziger & De Llano, LLP
  2. ↑ 2.0 2.1 2.2 Thoracentesis for Mesothelioma Patients, Mesothelioma.net
  3. ↑ 3.00 3.01 3.02 3.03 3.04 3.05 3.06 3.07 3.08 3.09 Malignant Pleural Effusion, StatPearls, National Library of Medicine (2024)
  4. ↑ 4.0 4.1 4.2 4.3 Mesothelioma Treatment Information, Mesothelioma Lawyer Center
  5. ↑ 5.0 5.1 5.2 5.3 5.4 5.5 5.6 5.7 5.8 Sensitivity and complications of thoracentesis and thoracoscopy: A systematic review and meta-analysis, Martinez-Zayas G et al., Respirology (2022)
  6. ↑ 6.0 6.1 6.2 6.3 6.4 6.5 6.6 Diagnostic capacity of BAP1 and MTAP in cytology from effusions, Kinoshita Y et al., Cancer Cytopathology (2022)
  7. ↑ 7.0 7.1 7.2 7.3 Ultrasound Guidance Decreases Complications and Improves the Cost of Care Among Patients Undergoing Thoracentesis and Paracentesis, Halm EA et al., Chest (2013)
  8. ↑ 8.0 8.1 Ultrasound guidance reduces pneumothorax rate and improves safety of thoracentesis in malignant pleural effusion: report on 445 consecutive patients with advanced cancer, World Journal of Surgical Oncology (2014)
  9. ↑ 9.0 9.1 9.2 9.3 9.4 Pleural Mesothelioma Overview, Danziger & De Llano, LLP
  10. ↑ 10.0 10.1 10.2 10.3 The Prevalence and Clinical Relevance of Non-expandable Lung in Malignant Pleural Mesothelioma: A Prospective, Single-Center Cohort Study of 229 Patients, Psaltis A et al., Annals of the American Thoracic Society (2019)
  11. ↑ 11.00 11.01 11.02 11.03 11.04 11.05 11.06 11.07 11.08 11.09 11.10 11.11 Updates on British Thoracic Society Statement on Pleural Disease, Lung (2024)
  12. ↑ 12.0 12.1 12.2 Mesothelioma Cancer Overview, Mesothelioma Lawyer Center
  13. ↑ 13.0 13.1 13.2 13.3 Confirmation that prophylactic irradiation of tracts (PIT) is not justified in routine treatment of MPM, University of Manchester Research Impact
  14. ↑ 14.0 14.1 14.2 14.3 14.4 14.5 PulmCrit — Large volume thoracentesis: Can we drain 'em dry?, Farkas J, EMCrit (2017)
  15. ↑ 15.0 15.1 15.2 15.3 15.4 15.5 15.6 15.7 Mesothelioma Treatment Costs, Danziger & De Llano, LLP
  16. ↑ 16.00 16.01 16.02 16.03 16.04 16.05 16.06 16.07 16.08 16.09 16.10 16.11 16.12 16.13 16.14 16.15 16.16 16.17 16.18 Complications of thoracentesis: incidence, risk factors, and strategies for prevention, Current Opinion in Pulmonary Medicine (2021)
  17. ↑ 17.00 17.01 17.02 17.03 17.04 17.05 17.06 17.07 17.08 17.09 17.10 Paracentesis for Peritoneal Mesothelioma, Mesothelioma.net
  18. ↑ 18.0 18.1 18.2 Delayed Diagnosis of Peritoneal Mesothelioma in Recurrent Ascites, Cureus (2024)
  19. ↑ 19.00 19.01 19.02 19.03 19.04 19.05 19.06 19.07 19.08 19.09 British Thoracic Society Guideline for pleural disease, Thorax (2023)
  20. ↑ 20.0 20.1 20.2 20.3 20.4 Mesothelioma Treatment Options, MesotheliomaAttorney.com
  21. ↑ Immune modulation in malignant pleural effusion: from microenvironment to therapeutic implications, Cancer Cell International (2024)
  22. ↑ 22.0 22.1 22.2 Chemotherapy for Mesothelioma, Mesothelioma Lawyer Center
  23. ↑ 23.0 23.1 23.2 23.3 Mesothelioma Treatment Guide, Mesothelioma.net
  24. ↑ 24.0 24.1 Malignant Peritoneal Mesothelioma Presenting with High Protein, High SAAG Ascites, Case Reports in Gastrointestinal Medicine (2022)
  25. ↑ 25.0 25.1 25.2 25.3 Peritoneal Mesothelioma, MesotheliomaAttorney.com
  26. ↑ 26.0 26.1 Incidence and risk factors of iatrogenic pneumothorax after thoracentesis, Journal of Thoracic Disease (2015)
  27. ↑ 27.0 27.1 27.2 27.3 Diagnosing Mesothelioma, Mesothelioma Lawyer Center
  28. ↑ 28.0 28.1 28.2 28.3 Mesothelioma Diagnosis Process, Danziger & De Llano, LLP
  29. ↑ 29.0 29.1 29.2 29.3 Mesothelioma Diagnosis Process, Mesothelioma.net
  30. ↑ 30.0 30.1 Palliative Care for Mesothelioma, Mesothelioma Lawyer Center
  31. ↑ Re-expansion Pulmonary Edema, Journal of Education & Teaching in Emergency Medicine (JETem)
  32. ↑ 32.0 32.1 32.2 32.3 32.4 Peritoneal Mesothelioma Guide, Mesothelioma Lawyer Center
  33. ↑ Mesothelioma Prognosis and Life Expectancy, Mesothelioma Lawyer Center
  34. ↑ 34.0 34.1 34.2 Peritoneal Mesothelioma Overview, Mesothelioma.net
  35. ↑ 35.0 35.1 35.2 Mesothelioma Types and Classification, Danziger & De Llano, LLP
  36. ↑ 36.0 36.1 36.2 36.3 36.4 Integrative approach to cytologic and molecular diagnosis of malignant pleural mesothelioma, Translational Lung Cancer Research (2020)
  37. ↑ 37.0 37.1 Mesothelioma Biopsy Types, Mesothelioma.net
  38. ↑ Relationship between positive peritoneal fluid cytology and ascites, Bibliomed (PDF)
  39. ↑ 39.0 39.1 39.2 Mesothelioma Diagnosis, MesotheliomaAttorney.com
  40. ↑ 40.0 40.1 Calculator: Light's Criteria for Exudative Pleural Effusions, Centre for Health Protection, Hong Kong
  41. ↑ 41.0 41.1 41.2 Mesothelioma Stages, Mesothelioma Lawyer Center
  42. ↑ Hyaluronic acid content of effusions as a diagnostic aid for malignant mesothelioma, Cancer (1985)
  43. ↑ 43.0 43.1 Utility of Hyaluronic Acid in Pleural Fluid for Differential Diagnosis of Pleural Effusions, Clinical Chemistry (1997)
  44. ↑ Malignant Peritoneal Mesothelioma Presenting with High Protein, High SAAG Ascites, Case Reports in Gastrointestinal Medicine (2022)
  45. ↑ Cite error: Invalid <ref> tag; no text was provided for refs named pubmedbap1
  46. ↑ 46.0 46.1 46.2 46.3 Loss of expression of BAP1 is a useful adjunct to distinguish mesothelioma from reactive mesothelial proliferations, Modern Pathology (2015)
  47. ↑ 47.0 47.1 Mesothelioma Staging Guide, Danziger & De Llano, LLP
  48. ↑ Diagnostic mesothelioma biomarkers in effusion cytology, University of Michigan Deep Blue Repository
  49. ↑ 49.0 49.1 49.2 49.3 A Combination of MTAP and BAP1 Immunohistochemistry in Pleural Effusion Cytology and Small Pleural Biopsies, Hida T et al., Diagnostic Cytopathology (2017)
  50. ↑ Effectiveness and Safety of Real-Time Transthoracic Ultrasound-Guided Thoracentesis, Diagnostics (2022)
  51. ↑ Real-time ultrasound-guided thoracentesis in the intensive care unit: prevalence of mechanical complications, Ultrasound Journal (2020)
  52. ↑ Pneumothorax Following Thoracentesis: A Systematic Review and Meta-analysis, Gordon CE et al., Archives of Internal Medicine (2010)
  53. ↑ 53.0 53.1 Mesothelioma Prognosis, MesotheliomaAttorney.com
  54. ↑ Mesothelioma Symptoms and Warning Signs, Danziger & De Llano, LLP
  55. ↑ 55.0 55.1 Prophylactic Irradiation of Tracts in Patients with Malignant Pleural Mesothelioma: A Systematic Review and Meta-analysis of Randomized Trials, Critical Reviews in Oncology/Hematology (2021)
  56. ↑ 56.0 56.1 56.2 Radiation Therapy for Mesothelioma, Mesothelioma.net
  57. ↑ Protocol for PIT: a phase III trial of prophylactic irradiation of tracts in patients with malignant pleural mesothelioma, BMJ Open (2016)
  58. ↑ Is there a role for prophylactic radiotherapy to intervention tract sites in patients with malignant pleural mesothelioma?, Translational Lung Cancer Research (2019)
  59. ↑ Prophylactic procedure tract radiotherapy for malignant pleural mesothelioma: A systematic review and meta-analysis, Radiotherapy and Oncology (2018)
  60. ↑ 60.0 60.1 60.2 Cost-effectiveness of indwelling pleural catheter compared with talc pleurodesis for malignant pleural effusion, Respirology (2017)
  61. ↑ 61.0 61.1 61.2 Effect of an Indwelling Pleural Catheter vs Chest Tube and Talc Pleurodesis for Relieving Dyspnea in Patients with Malignant Pleural Effusion: The TIME2 Randomized Clinical Trial, Davies HE et al., JAMA (2012)
  62. ↑ 62.0 62.1 Mesothelioma Surgery Options, Mesothelioma.net
  63. ↑ 63.0 63.1 Are We Choosing the Most Cost-Effective Treatment Option for Malignant Pleural Effusion?, Current Oncology (2024)
  64. ↑ 64.0 64.1 64.2 Indwelling pleural catheter efficacy and safety in malignant vs. non-malignant pleural effusions, Journal of Thoracic Disease (2025)
  65. ↑ CPT Code 32554 — Description and Fee Schedule 2026, PayerPrice
  66. ↑ Drainage Coding and Reimbursement Information, Argon Medical Devices (PDF)
  67. ↑ Malignant Pleural Effusion and Its Current Management: A Review, Medicina (2019)
  68. ↑ 68.0 68.1 68.2 Development and validation of a deep learning model using biomarkers in pleural effusion for prediction of malignant pleural mesothelioma, Semantic Scholar

Cite error: <ref> tag with name "pmcmpe" defined in <references> is not used in prior text.
Cite error: <ref> tag with name "elseviermpe" defined in <references> is not used in prior text.

Retrieved from "https://wikimesothelioma.com/index.php?title=Paracentesis_and_Thoracentesis&oldid=1686"